Fractyl Health, Inc. - Common Stock (GUTS)

Six-month data from 40 participants suggest that Revita helps limit weight regain after GLP-1 discontinuation.

Fractyl Health (NASDAQ: GUTS) released positive 6-month results from its REVEAL-1 study in obese patients who discontinued GLP-1 therapy.

Fractyl (GUTS) Q3 2025 Earnings Call Transcript

Discover the stocks with unexpected trading volume in today's session on the US markets.

Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million.

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.

Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.

Fractyl Health reports Q2 2025 net loss of $27.9M, missing EPS estimates. No revenue, but clinical progress in Revita and Rejuva programs. Stock dips amid investor concerns.

Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.